Treatment for MRSA no longer more costly than for susceptible Staph aureus infections

(Center for Disease Dynamics, Economics & Policy) A new study found that infections caused by one of the most common drug resistant bacteria in the US — methicillin-resistant Staphylococcus aureus, known as MRSA — are no more expensive to treat than MSSA, the methicillin-susceptible version of the same bacteria. These findings are contrary to earlier studies that have found that MRSA was much more expensive to treat than MSSA.

Comments